24 Apr

What to Expect from Merck’s Q1 Revenues and Earnings

WRITTEN BY Margaret Patrick

Financial performance in the first quarter

Wall Street analysts have forecasted Merck’s (MRK) revenues to be $10.48 billion, $10.92 billion, $11.34 billion, and $11.62 billion, in the first, second, third, and fourth quarters of fiscal 2019, respectively. These estimates imply a YoY change of 4.38%, 4.32%, 5.10%, and 5.68%, in the first, second, third, and fourth quarters of fiscal 2019, respectively.

Wall Street analysts have forecasted Merck’s SG&A (selling, general, and administrative) and R&D (research and development) expenses to be $2.54 billion and $1.96 billion, respectively. Analysts expect Merck’s non-GAAP EPS to be $1.05, $1.14, $1.25, and $1.23, in the first, second, third, and fourth quarters of fiscal 2019, respectively, which implies a YoY change of 0.43%, 7.60%, 5.10%, and 18.10%, in the first, second, third, and fourth quarters of fiscal 2019, respectively.

What to Expect from Merck’s Q1 Revenues and Earnings

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Financial performance in fiscal 2019

Wall Street analysts have forecasted Merck’s (MRK) revenues to be $44.42 billion, $10.92 billion, $47.00 billion, and $49.41 billion, in fiscal 2019, fiscal 2020, and fiscal 2021, respectively, which implies a YoY change of 5.03%, 5.80%, and 5.13% in fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

In its fourth-quarter earnings conference call, Merck has guided for fiscal 2019 revenues in the range of $43.2 billion to $44.7 billion, driven mainly by the robust performance of its vaccines, hospital, oncology, and specialty franchises. At mid-January rates, the company has assumed one percentage point negative revenue impact due to foreign exchange movements.

Wall Street analysts have forecasted Merck’s SG&A and R&D expenses to be $10.35 billion and $8.40 billion, respectively. In its fourth-quarter earnings conference call, Merck guided for a low to mid-single digit YoY increase in operating expenses in fiscal 2019.

Wall Street analysts have forecasted Merck’s non-GAAP EPS to be $4.68, $5.24, and $5.85 in fiscal 2019, fiscal 2020, and fiscal 2021, respectively, which implies a YoY change of 7.72%, 12.15%, and 11.51%, in fiscal 2019, fiscal 2020, and fiscal 2021, respectively. The company guided for non-GAAP EPS of $4.57 to $4.72 for fiscal 2019.

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.